Navigation Links
ImmunoVaccine Technologies Collaborates with Defence Research & Development Canada to Strengthen Canada's Ability to Deal with Biological Threats
Date:4/14/2009

HALIFAX, April 14 /PRNewswire/ - ImmunoVaccine Technologies Inc. (IVT), a vaccine development company, has announced the signing of a 3-year research agreement with Defence Research and Development Canada (DRDC). The research collaboration involves the preclinical application of IVT's DepoVax(TM) vaccine formulation to anthrax antigens to explore new methods to prevent, prepare for, and respond to biological threats.

"Dr. Les Nagata and his research team at DRDC are leaders in developing vaccines to fight deadly microbial pathogens and we look forward to this collaboration," remarked Dr. Marc Mansour, vice president of R&D at IVT. "Because our DepoVax(TM) formulation creates a long-lasting immune response and comes in a dry format that is easily reconstituted, it is well suited for the development of an effective anti-anthrax vaccine."

Anthrax is an acute infectious disease caused by the spore-forming bacterium Bacillus anthracis. Infection with anthrax is very serious, and potentially life threatening. Currently, to protect individuals who may come in contact with anthrax, immunization consists of three injections given 2 weeks apart, followed by three additional injections given at 6, 12, and 18 months. Annual booster injections of the vaccine are recommended thereafter.

ABOUT IVT

ImmunoVaccine Technologies Inc., winner of Canada's Top 10 Life Sciences Companies, is a privately held, vaccine development company. Through its own biotech research, patented VacciMax(R) and DepoVax(TM) technologies, and collaborations with partners, IVT creates vaccines with the potential to help save and improve lives around the world. www.immunovaccine.com.

ABOUT DRDC

DRDC is an agency of the Department of National Defence, responding to the scientific and technological needs of the Canadian Forces and national security communities.
'/>"/>

SOURCE IMMUNOVACCINE TECHNOLOGIES INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. ImmunoVaccine Technologies Inc. Nears Phase I Clinical Trials with Completion of Scientific Advisory Board
2. ImmunoVaccine Technologies appoints the Honourable Michael Kirby as Chair
3. ImmunoVaccine Technologies Patents DepoVax(TM) Vaccine Platform
4. ImmunoVaccine Technologies Congratulates Dr. Ramila Philip as One of PAs Best 50 Women in Business
5. ImmunoVaccine Technologies Broadens Its Patent Protection to Japan
6. ImmunoVaccine Technologies Presents at OneMed Place Finance Forum
7. ImmunoVaccine Technologies Signs Agreement with National Institutes of Health to Explore Vaccines for HIV and Malaria
8. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
9. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
10. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
11. BioMaxx Systems Inc. Signs Engagement Letter With Alcofuel Technologies for Provision of an Ethanol Micro-Refinery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/12/2014)... , Sept. 12, 2014 Research ... "Global Dry Film Photoresist Industry Report 2014" ... Dry Film Photoresist Industry Report 2014 is a professional ... global dry film photoresist industry . The ... definitions, classifications, applications and industry chain structure. The dry ...
(Date:9/12/2014)... -- On Thursday, September 11, 2014, the NASDAQ ... Average finished the day 0.12% lower at 17,049.00, and the ... broad based as seven out of ten sectors ended the ... ended the day at 741.83, down 0.33%, while the index ... initiated coverage on the following equities: Exelixis Inc. (NASDAQ: ...
(Date:9/11/2014)... RURO, Inc., a leading laboratory ... and sample management solutions provider, announces the release ... on the most recent version of its Limfinity® ... seen mass adoption, especially from multi-license environment customers. ... brought an entirely new User Interface and version ...
(Date:9/11/2014)... Lab researchers believes it has uncovered the secret ... layers of transition metal dichalcogenide (TMDC) materials, the ... and photonic applications. , Using two-photon excitation ... one of the most promising of 2D materials, ... dark states energy states in which single ...
Breaking Biology Technology:Global Dry Film Photoresist Industry Report 2014 2Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 2Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 3Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 4Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 5Limfinity® Version 5.1 Available 2Excitonic dark states shed light on TMDC atomic layers 2Excitonic dark states shed light on TMDC atomic layers 3
... Feb. 28, 2011 Idenix Pharmaceuticals, Inc. (Nasdaq: ... discovery and development of drugs for the treatment of ... the fourth quarter and year ended December 31, 2010. ... totaled $46.1 million. Business HighlightsIDX184 ...
... SAN DIEGO, Feb. 28, 2011 Verenium Corporation (Nasdaq: ... of high-performance specialty enzymes, today announced that Terminal 6, ... has successfully begun use of Verenium,s Purifine enzymatic degumming ... Argentina. Purifine enzymatic degumming is a novel process that ...
... (CTI) (Nasdaq and MTA: CTIC) announced today that it ... Conference on Thursday, March 3rd at 10:25 AM Pacific ... Center, Seattle, Washington. WBBA Life Science Innovation Northwest ConferenceCTI ... PM CETRoom 607, Washington State Conference CenterMedia Contact:Dan Eramian ...
Cached Biology Technology:Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2010 Financial Results 2Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2010 Financial Results 3Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2010 Financial Results 4Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2010 Financial Results 5Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2010 Financial Results 6Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2010 Financial Results 7World's Largest Soybean Processing Industrial Complex Converts Half of Capacity to Usage of Verenium's Purifine® PLC Enzymatic Degumming Process Engineered and Installed by Alfa Laval 2World's Largest Soybean Processing Industrial Complex Converts Half of Capacity to Usage of Verenium's Purifine® PLC Enzymatic Degumming Process Engineered and Installed by Alfa Laval 3World's Largest Soybean Processing Industrial Complex Converts Half of Capacity to Usage of Verenium's Purifine® PLC Enzymatic Degumming Process Engineered and Installed by Alfa Laval 4
(Date:9/12/2014)... extraction of type I collagen fibrils, in vitro as ... circular cross sections stay distributed in a range going ... of them. Jean Charvolin and Jean-Francois Sadoc from the ... therefore that, once the growth of the fibrils has ... be limited by internal physical stresses generated during the ...
(Date:9/12/2014)... strange thing happened on the way to dealing ... trillions of dollars, worth of previously unreachable oil ... environmental costs and benefits from "fracking," ... and chemicals deep into underground rock formations, are ... academic studies and government databases. The survey covers ...
(Date:9/12/2014)... Washington , September 12, 2014 ... source covering leading sectors including biometrics and mobile tech, issues ... launch of Apple Pay, its new payment service. ... founder of the Secure Identity and Biometrics Association (SIBA) and ... NXTD ) a company that is introducing its own ...
Breaking Biology News(10 mins):Conjecture on the lateral growth of Type I collagen fibrils 2Stanford-led study assesses the environmental costs and benefits of fracking 2Stanford-led study assesses the environmental costs and benefits of fracking 3Stanford-led study assesses the environmental costs and benefits of fracking 4Biometric Experts Comment on Launch of Apple Pay Smart Wallet Payment Service 2Biometric Experts Comment on Launch of Apple Pay Smart Wallet Payment Service 3Biometric Experts Comment on Launch of Apple Pay Smart Wallet Payment Service 4Biometric Experts Comment on Launch of Apple Pay Smart Wallet Payment Service 5
... single protein is critical in the cellular export of ... in the March issue of Cell Metabolism. , Hemochromatosis--which ... Western populations --causes tissues of the body to become ... lead to organ failure. , The new work, led ...
... protects the body's infection-fighting cells might also contribute to ... disease, UT Southwestern Medical Center researchers have found. , ... inhibits cell death in macrophages, which circulate in the ... foreign substances. The AIM-protected macrophages go on to encourage ...
... There are 300 million cases of malaria each year ... deaths occur in Africa, mostly in young children. One ... against malaria is drug resistance; resistance to chloroquine (CQ), ... throughout Africa, and resistance to sulfadoxine-pyrimethamine (SP), the first-developed ...
Cached Biology News:Iron exporter revealed that may explain common human disorder 2Iron exporter revealed that may explain common human disorder 3Molecule that usually protects infection-fighting cells may cause plaque deposits inside arteries 2Reducing malarial transmission in Africa 2
... expression of an N-terminal FLAG® fusion and ... marker from bicistronic mRNA. Two genes ... for transcription of a single message from ... for protein-protein interaction studies, multi-subunit proteins, and ...
Mouse monoclonal antibody raised against a partial recombinant PRG4. NCBI Entrez Gene ID = PRG4...
Mouse monoclonal antibody raised against a partial recombinant FAAH. NCBI Entrez Gene ID = FAAH...
Mouse monoclonal antibody raised against a partial recombinant ZNF167. NCBI Entrez Gene ID = ZNF167...
Biology Products: